The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense

Oncogene

Volumn 34, Issue 14, 2014, Pages 1799-1810

  Itahana, Y ^a   Han, R ^a   Barbier, S ^a   Lei, Z ^a   Rozen, S ^a   Itahana, K ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; GLUCOSE TRANSPORTER; PROBENECID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SLC2A9 PROTEIN, HUMAN; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN; URIC ACID;

ANTAGONISTS AND INHIBITORS; DNA DAMAGE; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; HUMAN; METABOLISM; MORTALITY; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANTIOXIDANTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DNA DAMAGE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HEP G2 CELLS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PROBENECID; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; URIC ACID;

EID: 84900969667     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.119     Document Type: Article

References (51)

1. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
2. Itahana Y, Itahana K. Emerging roles of mitochondrial p53 and ARF. Curr Drug Targets 2012; 13: 1633-1640.
3. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med (Berl) 2011; 89: 237-245.
4. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-1283.
5. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001; 477: 7-21.
6. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2010; 2: a001040.
7. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
8. Macip S, Igarashi M, Berggren P, Yu J, Lee SW, Aaronson SA. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 2003; 23: 8576-8585.
9. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
10. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004; 304: 596-600.
11. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010; 107: 7455-7460.
12. Yoon KA, Nakamura Y, Arakawa H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 2004; 49: 134-140.
13. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-1313.
14. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004; 279: 16229-16236.
15. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005; 37: 718-726.
16. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12: 355-366.
17. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501-514.
18. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA 2002; 99: 8467-8472.
19. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
20. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
21. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
22. Phay JE, Hussain HB, Moley JF. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 2000; 66: 217-220.
23. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-26838.
24. Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
25. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442.
26. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008; 83: 744-751.
27. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, Horisberger JD et al. Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol 2009; 297: F612-F619.
28. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372: 1953-1961.
29. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40: 430-436.
30. Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007; 3: e194.
31. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-6862.
32. Kellogg EW 3rd, Fridovich I. Liposome oxidation and erythrocyte lysis by enzymically generated superoxide and hydrogen peroxide. J Biol Chem 1977; 252: 6721-6728.
33. Liu JW, Chandra D, Rudd MD, Butler AP, Pallotta V, Brown D et al. Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene 2005; 24: 2020-2031.
34. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007; 26: 1749-1760.
35. Augustin R. The protein family of glucose transport facilitators: It's not only about glucose after all. IUBMB Life 2010; 62: 315-333.
36. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002; 19: 640-653.
37. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34: 78-84.
38. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-1799.
39. Cutler RG. Antioxidants and aging. Am J Clin Nutr 1991; 53: 373S-379S.
40. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1997; 94: 2528-2533.
41. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 344-348.
42. deLau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005; 58: 797-800.
43. Pietraforte D, Castelli M, Metere A, Scorza G, Samoggia P, Menditto A et al. Salivary uric acid at the acidic pH of the stomach is the principal defense against nitrite-derived reactive species: sparing effects of chlorogenic acid and serum albumin. Free Radic Biol Med 2006; 41: 1753-1763.
44. Campos-Arroyo D, Martinez-Lazcano JC, Melendez-Zajgla J. Probenecid is a chemosensitizer in cancer cell lines. Cancer Chemother Pharmacol 2012; 69: 495-504.
45. Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, Da Costa A et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA 2009; 106: 15501-15506.
46. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C et al Delayed ageing through damage protection by the Arf/p53 pathway. Noture 2007; 448: 375-379.
47. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem l997; 272: 19633-1 9636.
48. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi Ret oL Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12: 1151-1164.
49. Itahana K, Zhang Y. Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell 2008; 13: 542-553.
50. Clegg HV, Itahana Y, Itahana K, Ramalingam S, Zhang Y. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction. PLoS ONE 2012; 7: e38212.
51. Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013; 145: 554-565.